AU2004303792A1 - Anti-IGF-I receptor antibody - Google Patents

Anti-IGF-I receptor antibody Download PDF

Info

Publication number
AU2004303792A1
AU2004303792A1 AU2004303792A AU2004303792A AU2004303792A1 AU 2004303792 A1 AU2004303792 A1 AU 2004303792A1 AU 2004303792 A AU2004303792 A AU 2004303792A AU 2004303792 A AU2004303792 A AU 2004303792A AU 2004303792 A1 AU2004303792 A1 AU 2004303792A1
Authority
AU
Australia
Prior art keywords
antibody
therapeutic agent
seq
igf
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004303792A
Other languages
English (en)
Inventor
Nancy E. Dagdigian
Rajeeva Singh
Daniel J. Tavares
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunogen Inc
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/729,441 external-priority patent/US8034904B2/en
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of AU2004303792A1 publication Critical patent/AU2004303792A1/en
Priority to AU2011201809A priority Critical patent/AU2011201809A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2004303792A 2002-06-14 2004-12-07 Anti-IGF-I receptor antibody Abandoned AU2004303792A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011201809A AU2011201809A1 (en) 2002-06-14 2011-04-20 Anti-IGF-I receptor antibody

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/729,441 US8034904B2 (en) 2002-06-14 2003-12-08 Anti-IGF-I receptor antibody
US10/729,441 2003-12-08
PCT/US2004/038230 WO2005061541A1 (en) 2002-06-14 2004-12-07 Anti-igf-i receptor antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011201809A Division AU2011201809A1 (en) 2002-06-14 2011-04-20 Anti-IGF-I receptor antibody

Publications (1)

Publication Number Publication Date
AU2004303792A1 true AU2004303792A1 (en) 2005-07-07

Family

ID=36616549

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004303792A Abandoned AU2004303792A1 (en) 2002-06-14 2004-12-07 Anti-IGF-I receptor antibody

Country Status (13)

Country Link
EP (1) EP1692176A4 (de)
JP (1) JP2008502589A (de)
KR (1) KR20070001883A (de)
CN (1) CN1886424A (de)
AU (1) AU2004303792A1 (de)
BR (1) BRPI0417406A (de)
CA (1) CA2548065A1 (de)
CR (1) CR8426A (de)
EA (1) EA009807B1 (de)
EC (1) ECSP066595A (de)
IL (1) IL174770A0 (de)
MX (1) MXPA06005540A (de)
NO (1) NO20063155L (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190067275A (ko) 2009-12-21 2019-06-14 제넨테크, 인크. 항체 제제
RU2012153241A (ru) * 2010-05-11 2014-06-20 Авео Фармасьютикалз, Инк. Антитела к fgfr2
US9051561B2 (en) 2011-10-10 2015-06-09 Children's Hospital Los Angeles Asparaginase and treating diseases associated with asparagine dependence
CN103509117B (zh) * 2013-05-06 2016-03-09 江苏匡亚生物医药科技有限公司 抗人her2和人igf-ir的双特异性抗体及其制备方法和用途
CA3056573A1 (en) * 2017-05-30 2018-12-06 Teijin Pharma Limited Anti-igf-i receptor antibody

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002532685A (ja) * 1998-12-04 2002-10-02 ノバルティス アクチエンゲゼルシャフト 活性化ビトロネクチンレセプターαＶβ３をターゲティングするために有用な方法および組成物
EP1399483B1 (de) * 2001-01-05 2010-04-14 Pfizer Inc. Antikörper gegen den rezeptor für den insulinähnlichen wachstumsfaktor i
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
KR20050109489A (ko) * 2003-02-13 2005-11-21 화이자 프로덕츠 인크. 항-인슐린양 성장인자 ｉ 수용체 항체의 용도

Also Published As

Publication number Publication date
CA2548065A1 (en) 2005-07-07
KR20070001883A (ko) 2007-01-04
ECSP066595A (es) 2006-10-17
CN1886424A (zh) 2006-12-27
NO20063155L (no) 2006-08-11
EP1692176A1 (de) 2006-08-23
IL174770A0 (en) 2006-08-20
EP1692176A4 (de) 2008-11-12
EA009807B1 (ru) 2008-04-28
MXPA06005540A (es) 2006-08-17
EA200600931A1 (ru) 2006-10-27
JP2008502589A (ja) 2008-01-31
CR8426A (es) 2007-12-04
BRPI0417406A (pt) 2007-04-03

Similar Documents

Publication Publication Date Title
EP1532174B1 (de) Anti-igf-i-rezeptor-antikörper
US8034904B2 (en) Anti-IGF-I receptor antibody
US8933202B2 (en) AXL antibodies
AU2006236637B2 (en) Methods and compositions for treating or preventing cancer
US7972596B2 (en) Antibodies against vascular endothelial growth factor receptor-1
EP2708556B1 (de) Pharmazeutische zusammensetzung zur verwendung in einer kombinationstherapie zur prävention oder behandlung von c-met- oder angiogenesefaktorinduzierten erkrankungen
AU2004303792A1 (en) Anti-IGF-I receptor antibody
KR20050021001A (ko) 인간 인슐린-유사 성장인자-i 수용체 항체
CN111886257A (zh) 用于疾病和病症治疗和预防的抗-肾酶抗体

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted